These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27270285)

  • 1. Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.
    Stickles AM; Smilkstein MJ; Morrisey JM; Li Y; Forquer IP; Kelly JX; Pou S; Winter RW; Nilsen A; Vaidya AB; Riscoe MK
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4853-9. PubMed ID: 27270285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtle changes in endochin-like quinolone structure alter the site of inhibition within the cytochrome bc1 complex of Plasmodium falciparum.
    Stickles AM; de Almeida MJ; Morrisey JM; Sheridan KA; Forquer IP; Nilsen A; Winter RW; Burrows JN; Fidock DA; Vaidya AB; Riscoe MK
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1977-82. PubMed ID: 25605352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.
    Stickles AM; Ting LM; Morrisey JM; Li Y; Mather MW; Meermeier E; Pershing AM; Forquer IP; Miley GP; Pou S; Winter RW; Hinrichs DJ; Kelly JX; Kim K; Vaidya AB; Riscoe MK; Nilsen A
    Am J Trop Med Hyg; 2015 Jun; 92(6):1195-201. PubMed ID: 25918204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
    McConnell EV; Bruzual I; Pou S; Winter R; Dodean RA; Smilkstein MJ; Krollenbrock A; Nilsen A; Zakharov LN; Riscoe MK; Doggett JS
    ACS Infect Dis; 2018 Nov; 4(11):1574-1584. PubMed ID: 30117728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antimalarial compound ELQ-400 is an unusual inhibitor of the bc
    Song Z; Iorga BI; Mounkoro P; Fisher N; Meunier B
    FEBS Lett; 2018 Apr; 592(8):1346-1356. PubMed ID: 29574797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Endochin-Like Quinolones Exhibit Potent
    van Schalkwyk DA; Riscoe MK; Pou S; Winter RW; Nilsen A; Duffey M; Moon RW; Sutherland CJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinolone-3-diarylethers: a new class of antimalarial drug.
    Nilsen A; LaCrue AN; White KL; Forquer IP; Cross RM; Marfurt J; Mather MW; Delves MJ; Shackleford DM; Saenz FE; Morrisey JM; Steuten J; Mutka T; Li Y; Wirjanata G; Ryan E; Duffy S; Kelly JX; Sebayang BF; Zeeman AM; Noviyanti R; Sinden RE; Kocken CHM; Price RN; Avery VM; Angulo-Barturen I; Jiménez-Díaz MB; Ferrer S; Herreros E; Sanz LM; Gamo FJ; Bathurst I; Burrows JN; Siegl P; Guy RK; Winter RW; Vaidya AB; Charman SA; Kyle DE; Manetsch R; Riscoe MK
    Sci Transl Med; 2013 Mar; 5(177):177ra37. PubMed ID: 23515079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone.
    Skinner-Adams TS; Fisher GM; Riches AG; Hutt OE; Jarvis KE; Wilson T; von Itzstein M; Chopra P; Antonova-Koch Y; Meister S; Winzeler EA; Clarke M; Fidock DA; Burrows JN; Ryan JH; Andrews KT
    Commun Biol; 2019; 2():166. PubMed ID: 31069275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria.
    Frueh L; Li Y; Mather MW; Li Q; Pou S; Nilsen A; Winter RW; Forquer IP; Pershing AM; Xie LH; Smilkstein MJ; Caridha D; Koop DR; Campbell RF; Sciotti RJ; Kreishman-Deitrick M; Kelly JX; Vesely B; Vaidya AB; Riscoe MK
    ACS Infect Dis; 2017 Oct; 3(10):728-735. PubMed ID: 28927276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone.
    Lawres LA; Garg A; Kumar V; Bruzual I; Forquer IP; Renard I; Virji AZ; Boulard P; Rodriguez EX; Allen AJ; Pou S; Wegmann KW; Winter RW; Nilsen A; Mao J; Preston DA; Belperron AA; Bockenstedt LK; Hinrichs DJ; Riscoe MK; Doggett JS; Ben Mamoun C
    J Exp Med; 2016 Jun; 213(7):1307-18. PubMed ID: 27270894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.
    Staines HM; Burrow R; Teo BH; Chis Ster I; Kremsner PG; Krishna S
    J Antimicrob Chemother; 2018 Mar; 73(3):581-595. PubMed ID: 29237012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.
    Khositnithikul R; Tan-Ariya P; Mungthin M
    Malar J; 2008 Jan; 7():23. PubMed ID: 18226262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group.
    Looareesuwan S; Chulay JD; Canfield CJ; Hutchinson DB
    Am J Trop Med Hyg; 1999 Apr; 60(4):533-41. PubMed ID: 10348225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.
    Ke H; Ganesan SM; Dass S; Morrisey JM; Pou S; Nilsen A; Riscoe MK; Mather MW; Vaidya AB
    PLoS One; 2019; 14(4):e0214023. PubMed ID: 30964863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting Plasmodium cytochrome bc1: a complex issue.
    Barton V; Fisher N; Biagini GA; Ward SA; O'Neill PM
    Curr Opin Chem Biol; 2010 Aug; 14(4):440-6. PubMed ID: 20570550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
    Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
    J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
    McKeage K; Scott L
    Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimalarial quinolones: synthesis, potency, and mechanistic studies.
    Winter RW; Kelly JX; Smilkstein MJ; Dodean R; Hinrichs D; Riscoe MK
    Exp Parasitol; 2008 Apr; 118(4):487-97. PubMed ID: 18082162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
    Birth D; Kao WC; Hunte C
    Nat Commun; 2014 Jun; 5():4029. PubMed ID: 24893593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7-
    Nguyen W; Dans MG; Currie I; Awalt JK; Bailey BL; Lumb C; Ngo A; Favuzza P; Palandri J; Ramesh S; Penington J; Jarman KE; Mukherjee P; Chakraborty A; Maier AG; van Dooren GG; Papenfuss T; Wittlin S; Churchyard A; Baum J; Winzeler EA; Baud D; Brand S; Jackson PF; Cowman AF; Sleebs BE
    ACS Infect Dis; 2023 Mar; 9(3):668-691. PubMed ID: 36853190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.